- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192344
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
October 16, 2023 updated by: Abbisko Therapeutics Co, Ltd
A Phase 1, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021.
Preliminary antitumor activity will also be assessed.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will start with a dose escalation part of single-agent ABSK021 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability.
The expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types.
Preliminary antitumor activity will also be assessed.
Study Type
Interventional
Enrollment (Estimated)
85
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Siqing Fu, MD
- Phone Number: (713)792-4318
- Email: siqingfu@mdanderson.org
Study Contact Backup
- Name: YUAN LU
- Phone Number: +86-21-68910052
- Email: clinical@abbisko.cn
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90212
- Recruiting
- Precision NextGen Oncology
-
Contact:
- Kamlesh Sankhala, MD
- Email: info@nextgenonc.com
-
Contact:
- Phone Number: 1-424-777-0708
-
-
Colorado
-
Denver, Colorado, United States, 80218-1238
- Completed
- SCRI at Healthone
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Completed
- The Winship Cancer Institute of Emory University
-
-
Texas
-
Houston, Texas, United States, 77030
- Completed
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed solid tumors that have progressed on or intolerant to standard therapy or whom no standard therapy exists
- ECOG (electrocorticogram) performance status 0~1
- Life expectancy ≥ 3 months
- Adequate organ function and bone marrow function
For patients with tenosynovial giant cell tumor (TGCT) :
- A diagnosis of TGCT [i ncluding pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT TS) (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pathologist, and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a multi disciplinary tumor board);
- Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2 cm is required), assessed from MRI scans;
- Others
Exclusion Criteria:
- Known allergy or hypersensitivity to any component of the investigational drug product Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating factor 1 receptor) pathway inhibitors
- Known additional malignancy that is progressing or required active treatment within 3 years of the first dose of study treatment
- Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication
- Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment)
- Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence
- Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤2 severity (CTCAE v5.0) with the exception of alopecia and vitiligo
- Prior corticosteroids as anti-cancer therapy within a minimum of 2 weeks of the first dose of study drug
- Concomitant use of strong inhibitors or inducers of CYP3A4
- Active central nervous system (CNS) metastases
- Impaired cardiac function or clinically significant cardiac disease
- Patients with Gilbert's Syndrome or other underlying conditions that may lead to a greater likelihood of developing LFT(liver function test) abnormalities during the study
- Known human immunodeficiency virus or active hepatitis B, or active hepatitis C infection
- Refractory/uncontrolled ascites or pleural effusion
- Pregnant or nursing
For patients with tenosynovial giant cell tumor (TGCT) :
- Known allergy or hypersensitivity to any component of the investigational drug product
- For expansion part, previous treatment with CSF 1/CSF 1R pathway inhibitors (not applicable for TGCT patients in US)
- Others
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABSK021
Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by"3+3" escalation rules based on safety data until an MTD has been identified or a RDE.
For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose.
Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles.
|
ABSK021 oral capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of DLTs
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
DLT(dose-limiting toxicity)
|
At the end of Cycle 1 (each cycle is 28 days)
|
Incidence and Severity of AEs
Time Frame: Through study completion, an average of 6 months
|
Adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)
|
Through study completion, an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
Progression-Free Survival (PFS)
|
From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
DoR
Time Frame: From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
Duration of Response (DoR)
|
From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
DCR
Time Frame: 24 weeks post-dose
|
Disease Control Rate (DCR)
|
24 weeks post-dose
|
Cmax
Time Frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The peak plasma concentration of a drug after administration
|
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
tmax
Time Frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Time to reach Cmax
|
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Bioavailability
Time Frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The systemically available fraction of a drug
|
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Elimination half-life
Time Frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The time required for the concentration of the drug to reach half of its original value
|
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Siqing Fu, MD, M.D. Anderson Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2020
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
November 27, 2019
First Submitted That Met QC Criteria
December 9, 2019
First Posted (Actual)
December 10, 2019
Study Record Updates
Last Update Posted (Actual)
October 18, 2023
Last Update Submitted That Met QC Criteria
October 16, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABSK021-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
European Association for Endoscopic SurgeryWithdrawn
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on ABSK021
-
Abbisko Therapeutics Co, LtdRecruiting
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Abbisko Therapeutics Co, LtdActive, not recruitingTenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular SynovitisSpain, China, United States, Netherlands, Italy, Canada, Poland
-
Abbisko Therapeutics Co, LtdRecruitingAdvanced Pancreatic CancerChina
-
Abbisko Therapeutics Co, LtdNot yet recruiting